Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach - Related Studies

Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

This study is ongoing, but not recruiting participants.

Study NCT00004233. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer-Related Problem/Condition
		Esophageal Cancer
		Gastric Cancer

2	Additional conditions recognized in this trial
		Adenocarcinoma
		Esophageal Diseases
		Esophageal Neoplasms
		Stomach Neoplasms

3	More general conditions related to this trial
		Carcinoma
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Head and Neck Neoplasms
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Stomach Diseases

4	Interventions listed in this trial
		fluorouracil
		leucovorin calcium
		triacetyluridine

5	Additional drug interventions recognized in this trial
		Leucovorin

6	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Growth Substances
		Immunologic Factors
		Immunosuppressive Agents
		Micronutrients
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses
		Vitamin B Complex
		Vitamins

7	Sponsors listed in this trial
		Southwest Oncology Group
		National Cancer Institute (NCI)